Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis
Healthcare · Biotechnology · NasdaqCM
Catalyst Pharmaceuticals, Inc. (CPRX) posted $588.99M in revenue for fiscal 2025 (up 19.8% year over year), at a 36.4% net margin, and has compounded revenue about 37.7%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. has grown revenue from $0 to $588.99M over the last 10 fiscal years, compounding about 37.7% a year. The most recent year was up 19.8%, so growth has cooled from its longer-run pace.
Net margin sits at 36.4%, up 3.1 points year over year on a 85.2% gross margin.
At today's valuation the market is pricing in roughly 6.6% annual free-cash-flow growth — versus the 35.9% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven. The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from Catalyst Pharmaceuticals, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Catalyst Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $500,000 | $102.31M | $119.07M | $140.83M | $214.20M | $398.20M | $491.73M | $588.99M |
| Gross profit | — | — | — | $87.55M | $102.03M | $118.95M | $179.81M | $346.24M | $422.89M | $501.74M |
| Net income | $-18.07M | $-18.41M | $-34.00M | $31.88M | $74.98M | $39.48M | $83.08M | $71.41M | $163.89M | $214.33M |
| Net margin | — | — | -6800.7% | 31.2% | 63.0% | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
Source: Catalyst Pharmaceuticals, Inc. SEC filings (10-K). 24 years of history available in the interactive view.
Catalyst Pharmaceuticals, Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 93.2% while revenue rose 19.8% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Inventory building faster than salesInventory rose 90.2% versus revenue 19.8% — possible overproduction or softening demand.
- Share count rising (dilution)Shares outstanding grew 19.0% over 4 years (103M → 122.5M) — existing holders' stakes are being diluted.
What growth is priced into CPRX stock?
At today's market cap of $3.84B, Catalyst Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $208.61M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 35.9%/yr over the last five fiscal years and revenue 37.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 24 years of Catalyst Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CPRX in your portfolio →
Catalyst Pharmaceuticals, Inc. financial history by metric
Compare Catalyst Pharmaceuticals, Inc. with peers
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc. — frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s revenue?
Catalyst Pharmaceuticals, Inc. (CPRX) reported revenue of $588.99M for fiscal year 2025, up 19.8% from the prior year, according to its SEC filings.
Is Catalyst Pharmaceuticals, Inc. profitable?
Yes. CPRX earned net income of $214.33M in fiscal 2025, a net margin of 36.4%.
What is CPRX's P/E ratio?
Catalyst Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 18.1 based on the latest data in our nightly-refreshed cache.
How fast is Catalyst Pharmaceuticals, Inc. growing?
CPRX's revenue grew at roughly 37.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Catalyst Pharmaceuticals, Inc. have?
As of fiscal year 2025, CPRX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Catalyst Pharmaceuticals, Inc.'s gross margin?
CPRX's gross margin was 85.2% in fiscal 2025 — gross profit of $501.74M on revenue of $588.99M.
What is Catalyst Pharmaceuticals, Inc.'s market cap?
Catalyst Pharmaceuticals, Inc. (CPRX) has a market capitalization of about $3.84B, based on the latest data in our nightly-refreshed cache.
When does Catalyst Pharmaceuticals, Inc.'s fiscal year end?
CPRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CPRX stock?
At today's market cap of $3.84B, Catalyst Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 6.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $208.61M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 35.9%/yr over the last five fiscal years and revenue 37.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Catalyst Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 24 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.